Abstract:Rabies, caused by the rabies virus (RABV), is the most fatal zoonotic disease. It is a neglected tropical disease which remains a major public health problem, causing approximately 59,000 deaths worldwide annually. Despite the existence of effective vaccines, the high incidence of human rabies is mainly linked to tedious vaccine immunisation procedures and the overall high cost of post-exposure prophylaxis. Therefore, it is necessary to develop an effective vaccine that has a simple procedure and is affordable to prevent rabies infection in humans. RABV belongs to the genus Lyssavirus and family Rhabdoviridae. Previous phylogenetic analyses have identified seven major clades of RABV in China (China I-VII), confirmed by analysing nucleotide sequences from both the G and N proteins. This study evaluated the immunogenicity and protective capacity of SYS6008, an mRNA rabies vaccine expressing rabies virus glycoprotein, in mice and cynomolgus macaques. We demonstrated that SYS6008 induced sufficient levels of rabies neutralising antibody (RVNA) in mice. In addition, SYS6008 elicited strong and durable RVNA responses in vaccinated cynomolgus macaques. In the pre-exposure prophylaxis murine model, one or two injections of SYS6008 at 1/10 or 1/30 of dosage provided protection against a challenge with a 30-fold LD<sub>50</sub> of rabies virus (China I and II clades). We also demonstrated that in the post-exposure prophylaxis murine model, which was exposed to lethal rabies virus (China I-VII clades) before vaccination, one or two injections of SYS6008 at both 1/10 and 1/30 dosages provided better protection against rabies virus challenge than the immunization by five injections of commercial vaccines at the same dosage. In addition, we proved that SYS6008-induced RVNAs could neutralise RABV from the China I-VII clades. Finally, 1/10 of the dosage of SYS6008 was able to stimulate significant RABV-G specificity in the T cell response. Furthermore, we found that SYS6008 induced high cellular immunity, including RABV-G-specific T cell responses and memory B cells. Our results imply that the SYS6008 rabies vaccine, with a much simpler vaccination procedure, better immunogenicity, and enhanced protective capacity, could be a candidate vaccine for post-exposure prophylaxis of rabies infections.

Novel Approaches to the Prevention and Treatment of Rabies.

Protection Against CNS-Targeted Rabies Virus Infection is Dependent upon Type-1 Immune Mechanisms Induced by Live-Attenuated Rabies Vaccines

Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs

Enhancement of Blood–brain Barrier Permeability is Required for Intravenously Administered Virus Neutralizing Antibodies to Clear an Established Rabies Virus Infection from the Brain and Prevent the Development of Rabies in Mice

Rabies – epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review

Treat the “untreatable” by a Photothermal Agent: Triggering Heat and Immunological Responses for Rabies Virus Inactivation

Current status of human rabies prevention: remaining barriers to global biologics accessibility and disease elimination

Preexposure and Postexposure Prophylaxis of Rabies With Adeno-Associated Virus Expressing Virus-Neutralizing Antibody in Rodent Models

Rabies Vaccine for Prophylaxis and Treatment of Rabies: A Narrative Review

Research Progress on Neutralizing Epitopes and Antibodies for the Rabies Virus

Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies

New developments in rabies vaccination

Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection

Efficiency of Live Attenuated and Inactivated Rabies Viruses in Prophylactic and Post Exposure Vaccination Against the Street Virus Strain

A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses

Rabies in a postpandemic world: resilient reservoirs, redoubtable riposte, recurrent roadblocks, and resolute recidivism

Management of Rabies in Humans.

Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms

Update on lyssaviruses and rabies: will past progress play as prologue in the near term towards future elimination?

The Immune Response to Rabies Virus Infection

Development of mRNA rabies vaccines